Formulations of deferasirox and methods of making the same
The disclosure provides for improved pharmaceutical compositions containing deferasirox (DFX) and methods of manufacturing the same. In particular, the compositions are prepared using thermokinetic compounding and provide improved properties as well as more efficient methods of manufacture.
1. A method of treating a subject for chronic iron overload in a subject who experiences a suboptimal or inadequate response to non-amorphous dispersions or crystalline forms of deferasirox (DFX) comprising administering to the subject a pharmaceutical composition comprising an amorphous solid dispersion of DFX and one or more pharmaceutically acceptable excipients, wherein said composition has a single glass transition temperature.
2. The method of claim 1 , wherein the amorphous solid dispersion of DFX is thermally processed into a composite by thermokinetic compounding, and the non-amorphous dispersion or crystalline form of DFX is thermally processed by a process other than thermokinetic compounding.
3. The method of claim 1 , wherein the subject has a blood disorder.
4. The method of claim 3 , wherein the blood disorder is β-thalassemia.
5. The method of claim 3 , wherein the blood disorder is chronic anemia.
6. The method of claim 1 , wherein the bioavailability of the amorphous solid dispersion of DFX is independent of any food effect.
7. The method of claim 6 , wherein the food effect is consuming a high fat meal.